knowledge -WSS

knowledge

author：knowledge 2025-09-03 15:17:28 - browse：687

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

WSS

EPA limits use of carcinogenic gas for sterilizing medical devices

Morphosys mixed study results for blood cancer drug

Why scientists need input from humanists on sensitive research

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

PBM reforms clear House panel

PBM reforms clear House panel

leisure time

knowledge

knowledge

Medical leaders decry Supreme Court decision on affirmative action

As AI in medicine takes off, can 'human in the loop' prevent harm?

Medical leaders decry Supreme Court decision on affirmative action

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Continuity nursing helped my family in our darkest PICU moments

Medicare coverage of Wegovy, once blocked, now looks possible

Medical leaders decry Supreme Court decision on affirmative action

World's first CRISPR

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

hotspot

PBM reforms clear House panel

Boston's new lab space is opening empty

NYU radiologists take on the challenge of expensive MRI machines

Does good food count as health care? Study aims to find out

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

As AI in medicine takes off, can 'human in the loop' prevent harm?

explore

Wikipedia

knowledge

explore